Osteosarcoma - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 287
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O52BF4A8A59EN
Leaflet:

Download PDF Leaflet

Osteosarcoma - Pipeline Review, H2 2017
Osteosarcoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteosarcoma - Companies Involved in Therapeutics Development
Advaxis Inc
Advenchen Laboratories LLC
Amgen Inc
AntiCancer Inc
Arrowhead Pharmaceuticals Inc
AVEO Pharmaceuticals Inc
Bayer AG
Bellicum Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celldex Therapeutics Inc
Cellmid Ltd
CorMedix Inc
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Intezyne Technologies Inc
Ipsen SA
Isofol Medical AB
Johnson & Johnson
MacroGenics Inc
MD Biosciences GmbH
Merck & Co Inc
Merck KGaA
Novartis AG
Oncolys BioPharma Inc
Pfizer Inc
Teijin Pharma Ltd
Osteosarcoma - Drug Profiles
12-B80 - DRUG PROFILE
3D-QM - DRUG PROFILE
3D-QMS - DRUG PROFILE
A-1R - Drug Profile
ADXS-HER2 - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
AM-7209 - Drug Profile
apatinib - Drug Profile
AT-69 - Drug Profile
AU-101 - Drug Profile
AV-203 - Drug Profile
avelumab - Drug Profile
axitinib - Drug Profile
BMTP-11 - Drug Profile
CAB-102 - Drug Profile
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Celyvir - Drug Profile
cisplatin SR - Drug Profile
daunorubicin hydrochloride - Drug Profile
dihydroartemisinin - Drug Profile
DS-5272 - Drug Profile
enoblituzumab - Drug Profile
everolimus - Drug Profile
glembatumumab vedotin - Drug Profile
ipilimumab + nivolumab - Drug Profile
irinotecan hydrochloride - Drug Profile
JNJ-7107 - Drug Profile
lenvatinib mesylate - Drug Profile
ligerin - Drug Profile
MD-401A - Drug Profile
Minnelide - Drug Profile
Modufolin - Drug Profile
Monoclonal Antibody for Osteosarcoma - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
OBP-702 - Drug Profile
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
radium Ra 223 dichloride - Drug Profile
RSF-101 - Drug Profile
SEN-461 - Drug Profile
sirolimus albumin-bound - Drug Profile
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
Small Molecules to Inhibit MDM2 for Osteosarcoma - Drug Profile
taurolidine - Drug Profile
Vaccine for Osteosarcoma - Drug Profile
VIMO-001 - Drug Profile
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Osteosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteosarcoma - Pipeline by Advaxis Inc, H2 2017
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
Osteosarcoma - Pipeline by Amgen Inc, H2 2017
Osteosarcoma - Pipeline by AntiCancer Inc, H2 2017
Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by Bayer AG, H2 2017
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2017
Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Osteosarcoma - Pipeline by Cellmid Ltd, H2 2017
Osteosarcoma - Pipeline by CorMedix Inc, H2 2017
Osteosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Osteosarcoma - Pipeline by Eisai Co Ltd, H2 2017
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2017
Osteosarcoma - Pipeline by Intezyne Technologies Inc, H2 2017
Osteosarcoma - Pipeline by Ipsen SA, H2 2017
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2017
Osteosarcoma - Pipeline by Johnson & Johnson, H2 2017
Osteosarcoma - Pipeline by MacroGenics Inc, H2 2017
Osteosarcoma - Pipeline by MD Biosciences GmbH, H2 2017
Osteosarcoma - Pipeline by Merck & Co Inc, H2 2017
Osteosarcoma - Pipeline by Merck KGaA, H2 2017
Osteosarcoma - Pipeline by Novartis AG, H2 2017
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2017
Osteosarcoma - Pipeline by Pfizer Inc, H2 2017
Osteosarcoma - Pipeline by Teijin Pharma Ltd, H2 2017
Osteosarcoma - Dormant Projects, H2 2017
Osteosarcoma - Dormant Projects, H2 2017 (Contd..1), H2 2017
Osteosarcoma - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Osteosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Advaxis Inc
Advenchen Laboratories LLC
Amgen Inc
AntiCancer Inc
Arrowhead Pharmaceuticals Inc
AVEO Pharmaceuticals Inc
Bayer AG
Bellicum Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celldex Therapeutics Inc
Cellmid Ltd
CorMedix Inc
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Intezyne Technologies Inc
Ipsen SA
Isofol Medical AB
Johnson & Johnson
MacroGenics Inc
MD Biosciences GmbH
Merck & Co Inc
Merck KGaA
Novartis AG
Oncolys BioPharma Inc
Pfizer Inc
Teijin Pharma Ltd
Skip to top


Osteosarcoma - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 255 pages
Sutro Biopharma, Inc. - Product Pipeline Review - 2016 US$ 1,500.00 Feb, 2016 · 34 pages
Wegener Polyangiitis - Pipeline Review, H2 2015 US$ 2,000.00 Dec, 2015 · 66 pages
Adenovirus Infections - Pipeline Review, H1 2014 US$ 2,000.00 Jun, 2014 · 64 pages
Seikagaku Corporation - Product Pipeline Review - 2015 US$ 1,500.00 Nov, 2015 · 29 pages

Ask Your Question

Osteosarcoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: